CTK Biotech is proud to announce that the OnSite Dengue IgG Rapid Test is included in the CDC’s two-step testing algorithm for concluding evidence of prior acute dengue virus infection prior to vaccination with Sanofi’s Dengvaxia Dengue vaccine. In the United States, Dengvaxia is available for use in children and adolescents 9–16 years old with laboratory-confirmed previous dengue virus infection and living in an area where dengue is endemic to reduce the risk of hemorrhagic dengue fever in re-infection.
The OnSite Dengue IgG Rapid Test is a single-use, lateral flow immunoassay to qualitatively detect anti-dengue virus IgG in serum/plasma or whole blood specimens as evidence of past dengue infection.
Dr. Vasco Liberal, CTK’s VP of Development, commented, “This is the first rapid test be used to screen vaccine candidates at the point of vaccination, in such a way that a positive test result indicates past infection, a requirement for Dengvaxia vaccination. We are excited to see more applications with the lateral flow rapid test technology, and we are proud to make a contribution to such a unique ‘test and vaccinate’ program.“